Bladder cancer: Clinical and pathological profile

References

• Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66(Suppl 6A)4–34
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin 2008; 58: 71–96
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004; 46: 170–6
   PubMed Web of Science ®Google Scholar
• Eble JN, Sauter G, Epstein JI, Sesterhenn IAE. World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon 2004
   Google Scholar
• Sauter G, Algaba F, Amin MB, Busch C, Cheville J, Gasser T, . Non-invasive urothelial neoplasias. World Health Organization classification of tumors: pathology and genetics of tumors of the urinary system and male genital organs, JN Eble, G Sauter, JI Epstein, IA Sesterhenn, et al. IARC Press, Lyon 2004
   Google Scholar
• Lopez-Beltran A, Sauter G, Gasser T, Hartmann A, Schmitz-Dräger BJ, Helpap B, . Urothelial tumors: infiltrating urothelial carcinoma. World Health Organization classification of tumors: pathology and genetics of tumors of the urinary system and male genital organs, JN Eble, G Sauter, JI Epstein, IA Sesterhenn, et al. IARC Press, Lyon 2004
   Google Scholar
• Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 2004; 13: 143–53
   Web of Science ®Google Scholar
• Reuter VE. The pathology of bladder cancer. Urology 2006; 67(3 Suppl 1)11–7
   PubMed Web of Science ®Google Scholar
• Pavone-Macaluso M, Lopez-Beltran A, Aragona F, Bassi P, Fitzpatrick JM. The pathology of bladder cancer: an update on selected issues. BJU Int 2006; 98: 1161–5
   PubMed Web of Science ®Google Scholar
• Kretschmer HL. Hematuria: a clinical study based on 933 consecutive cases. Surg Gynecol Obstet 1925; 40: 683–8
   Google Scholar
• Varkarakis MJ, Gaeta J, Moore RH, Murphy GP. Superficial bladder tumor: aspects of clinical progression. Urology 1974; 4: 414–20
   PubMedGoogle Scholar
• Lee LW, Davis E, Jr. Gross urinary hemorrhage: a symptom, not a disease. JAMA 1953; 153: 782–4
   PubMed Web of Science ®Google Scholar
• Mohr DN, Offord KP, Owen RA, Melton LJ III. Asymptomatic microhematuria and urologic disease: a population-based study. JAMA 1986; 256: 224–9
   PubMed Web of Science ®Google Scholar
• Golin AL, Howard RS. Asymptomatic microscopic hematuria. J Urol 1980; 124: 389–91
   PubMed Web of Science ®Google Scholar
• Malmström PU. Time to abandon testing for microscopic haematuria in adults?. BMJ 2003; 326: 813–5
   PubMed Web of Science ®Google Scholar
• Montironi R, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L. Morphological diagnosis of urothelial neoplasms. J Clin Pathol 2008; 61: 3–10
   PubMed Web of Science ®Google Scholar
• Höglund M. On the origin of syn- and metachronous urothelial carcinomas. Eur Urol 2007; 51: 1185–93
   PubMed Web of Science ®Google Scholar
• Droller MJ. Bladder cancer: state-of-the-art care. CA Cancer J Clin 1998; 48: 269–84
   PubMed Web of Science ®Google Scholar
• Kaye KW, Lange PH. Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol 1982; 128: 31–3
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Buch C, Norlen BJ. Recurrence, progression, and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 1987; 21: 185–95
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466–5
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24: 778–89
   PubMed Web of Science ®Google Scholar
• Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995; 153: 1823–6
   PubMed Web of Science ®Google Scholar
• Kakizoe T. Development and progression of urothelial carcinoma. Cancer Sci 2006; 97: 821–8
   PubMed Web of Science ®Google Scholar
• Jimenez RE, Gheiler E, Oskanian P, Tiguert R, Sakr W, Wood DP, Jr, et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol 2000; 24: 980–7
   PubMed Web of Science ®Google Scholar
• Habuchi T. Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications. Int J Urol 2005; 12: 709–16
   PubMed Web of Science ®Google Scholar
• Denzinger S, Mohren K, Knuechel R, Wild PJ, Burger M, Wieland WF, et al. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. Hum Pathol 2006; 37: 143–51
   PubMed Web of Science ®Google Scholar
• Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005; 11: 6512–9
   PubMed Web of Science ®Google Scholar
• Epstein JI, Amin MB, Reuter VR, Mostofi FK, Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22:1435–48.
   PubMed Web of Science ®Google Scholar
• Montironi R, Lopez-Beltran A, Mazzuchelli R, Bostwick DG. Classification and grading of the non-invasive bladder neoplasms: recent advances and controversies. J Clin Pathol 2003; 56: 91–5
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Cheng L, Andersson L, Brausi M, de Matteis A, Montironi R, et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch 2002; 440: 3–11
   PubMed Web of Science ®Google Scholar
• Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999; 154: 721–7
   PubMed Web of Science ®Google Scholar
• Taylor DC, Bhagavan BS, Larsen MP, Cox JA, Epstein JI. Papillary urothelial hyperplasia. A precursor to papillary neoplasms. Am J Surg Pathol 1996; 20: 1481–8
   PubMed Web of Science ®Google Scholar
• Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999; 23: 443–7
   PubMed Web of Science ®Google Scholar
• Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002; 62: 809–18
   PubMed Web of Science ®Google Scholar
• Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996; 78: 870–87
   PubMedGoogle Scholar
• Cheng L, Cheville JC, Leibovich BC, Weaver AL, Egan KS, Spotts BE, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999; 85: 2469–74
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Luque RJ, Moreno A, Bollito E, Carmona E, Montironi R. The pagetoid variant of bladder urothelial carcinoma in situ. A clinicopathological study of 11 cases. Virchows Arch 2002; 441: 148–53
   PubMed Web of Science ®Google Scholar
• McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol 2001; 25: 356–62
   PubMed Web of Science ®Google Scholar
• Farrow GM, Utz DC. Observations on microinvasive transitional cell carcinoma of the urinary bladder. Clin Oncol 1982; 1: 609–14
   Google Scholar
• Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. World Health Organization, Geneva 1973
   Google Scholar
• Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodríguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 73–8
   PubMed Web of Science ®Google Scholar
• Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083–6
   PubMed Web of Science ®Google Scholar
• Jakse G, Loidl W, Seeber G, Hofstädter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?. J Urol 1987; 137: 39–43
   PubMed Web of Science ®Google Scholar
• Lopez-Beltrana A, Bassi PF, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol 2004; 45: 257–66
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Mikuz G. Urothelial papillary (exophytic) neoplasms. Virchows Arch 2002; 441: 109–16
   PubMed Web of Science ®Google Scholar
• Cheng L, Darson M, Cheville JC, Neumann RM, Zincke H, Nehra A, et al. Urothelial papilloma of the bladder. Clinical and biologic implications. Cancer 1999; 86: 2098–101
   PubMed Web of Science ®Google Scholar
• McKenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol 2003; 16: 623–9
   PubMed Web of Science ®Google Scholar
• Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer 1999; 86: 2102–8
   PubMed Web of Science ®Google Scholar
• Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/International Society of Urologic Pathology. Mod Pathol 2001; 14: 267–72
   PubMed Web of Science ®Google Scholar
• Oosterlinck W, Solsona E, Akaza H, Busch C, Goebell PJ, Malmstrom PU, et al. Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. Urology; 66(6 Suppl 2005; 1): 75–8
   Web of Science ®Google Scholar
• Jones TD, Cheng L. Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol 2006; 175: 1995–2003
   PubMed Web of Science ®Google Scholar
• Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol 2000; 13: 1315–23
   PubMed Web of Science ®Google Scholar
• Fujii Y, Kawakami S, Koga F, Nemoto T, Kihara K. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 2003; 92: 559–62
   PubMed Web of Science ®Google Scholar
• Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001; 165: 1124–8
   PubMed Web of Science ®Google Scholar
• Holmang S, Johansson SL. Stage Ta–T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002; 167: 1634–7
   PubMed Web of Science ®Google Scholar
• Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol; 168 1998; 2003: 968–72
   Google Scholar
• Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Pauwels RP, Newling DW, ten Kate F. Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol; 55 1998; 2002: 900–5
   Google Scholar
• Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Navone R. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. Am J Surg Pathol 2001; 25: 1528–33
   PubMed Web of Science ®Google Scholar
• Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 2002; 60: 315–9
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002; 198: 245–51
   PubMed Web of Science ®Google Scholar
• Sung MT, Maclennan GT, Lopez-Beltran A, Montironi R, Cheng L. Natural history of urothelial inverted papilloma. Cancer 2006; 107: 2622–7
   PubMed Web of Science ®Google Scholar
• Sung MT, Eble JN, Wang M, Tan PH, Lopez-Beltran A, Cheng L. Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Mod Pathol 2006; 19: 1289–94
   PubMed Web of Science ®Google Scholar
• Jones TD, Zhang S, Lopez-Beltran A, Eble JN, Sung MT, MacLennan GT, et al. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Am J Surg Pathol 2007; 31: 1861–7
   PubMed Web of Science ®Google Scholar
• Barbisan F, Santinelli A, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, et al. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer 2008; 112: 636–44
   PubMed Web of Science ®Google Scholar
• Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC cancer staging manual. Springer, New York 2002
   Google Scholar
• Cheng L, Weaver AL, Leibovich BC, Ramnani DM, Neumann RM, Sherer BG, et al. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer 2000; 88: 2326–32
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 2002; 60: 822–4
   PubMed Web of Science ®Google Scholar
• Esrig D, Freeman JA, Stein JP, Skinner DG. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol 1997; 15: 154–60
   PubMedGoogle Scholar
• Bochner BH, Kattan MW, Vora KC, International Bladder Cancer Nomogram Consortium. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006;24:3967–72.
   PubMed Web of Science ®Google Scholar
• Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999; 161: 1494–7
   PubMed Web of Science ®Google Scholar
• Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B. The value of a second transurethral resection in evaluating patients with bladder tumors. Eur Urol 2003; 43: 241–5
   PubMed Web of Science ®Google Scholar
• Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, et al. Bladder Cancer Research Consortium. Cancer specific outcomes in patients with pT0 disease following radical cystectomy. J Urol 2006; 175: 1645–9
   PubMed Web of Science ®Google Scholar
• Bol M, Baak J, Buhr-Wildhagen S. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003; 169: 1291–4
   PubMed Web of Science ®Google Scholar
• Tosoni I, Wagner U, Sauter G, Egloff M, Knönagel H, Alund G, et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 2000; 85: 48–53
   PubMed Web of Science ®Google Scholar
• Van der Meijden A, Sylvester R, Collette L, Bono A, ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials. J Urol 2000; 164: 1533–7
   PubMed Web of Science ®Google Scholar
• Cheng L, Neumann RM, Weaver AL, Spotts B, Bostwick DG. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 1999; 17: 3182–7
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Cheng L. Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. Pathology 2003; 35: 484–91
   PubMed Web of Science ®Google Scholar
• Jimenez RE, Keany TE, Hardy HT, Amin MB. pT1 Urothelial carcinoma of the bladder: criteria for diagnosis, pitfalls, and clinical implications. Adv Anat Pathol 2000; 7: 13–25
   PubMed Web of Science ®Google Scholar
• Angulo JC, Lopez JI, Grignon DJ, Sanchez-Chapado M. Muscularis mucosae differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 1995; 45: 47
   PubMed Web of Science ®Google Scholar
• Hasui Y, Osada Y, Kitada S, Nishi S. Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology 1994; 43: 782–6
   PubMed Web of Science ®Google Scholar
• Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. The importance of the depth of invasion in stage T1 bladder carcinoma bladder carcinoma: a prospective cohort study. J Urol 1997; 157: 800–4
   PubMed Web of Science ®Google Scholar
• Platz CE, Cohen MB, Jones MP, Olson DB, Lynch CF. Is microstaging of early invasive cancer of the urinary bladder possible or useful?. Mod Pathol 1996; 11: 1035–9
   Google Scholar
• Ro JY, Ayala AG, el-Naggar A. Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am J Surg Pathol 1987; 11: 668–73
   PubMed Web of Science ®Google Scholar
• Sozen S, Akbal C, Sokmensuer C, Ekici S, Ozen H. Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory). Urol Int 2002; 69: 200–6
   PubMed Web of Science ®Google Scholar
• Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990; 66: 543–8
   PubMed Web of Science ®Google Scholar
• Harry W, Herr S, Donat M, Reuter VE. Management of low grade papillary bladder tumors. J Urol 2007; 178: 1201–5
   PubMed Web of Science ®Google Scholar
• Tokgoz H, Turkolmez K, Resorlu B, Kose K, Tulunay O, Beduk Y. Pathological staging of muscle invasive bladder cancer. Is substaging of pT2 tumors really necessary?. Int Braz J Urol 2007; 33: 777–84
   PubMedGoogle Scholar
• Bayraktar Z, Gorbuz G, Ihsan AT, Sevin G. Staging error in the bladder tumor: the correlation between stage of TUR and cystectomy. Int J Urol Nephrol 2002; 33: 627–9
   Google Scholar
• Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 1997; 37: 41–9
   PubMed Web of Science ®Google Scholar
• Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, et al. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol 2004; 17(12 Pt 1)640–5
   Web of Science ®Google Scholar
• Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, et al. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer 2003; 98: 955–61
   PubMed Web of Science ®Google Scholar
• Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol 2006; 37: 726–34
   PubMed Web of Science ®Google Scholar
• Esrig D, Freeman JA, Elmajian DA, Stein JP, Chen SC, Groshen S, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol 1996; 156: 1071–6
   PubMed Web of Science ®Google Scholar
• Pagano F, Bassi P, Ferrante GL, Piazza N, Abatangelo G, Pappagallo GL, et al. Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. J Urol 1996; 155: 244–7
   PubMed Web of Science ®Google Scholar
• Leissner J, Koeppen C, Wolf HK. Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol 2003; 169: 955–60
   PubMed Web of Science ®Google Scholar
• Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 2005; 23: 6533–9
   PubMed Web of Science ®Google Scholar
• Reuter VE. Lymphovascular invasion as an independent predictor of recurrence and survival in node-negative bladder cancer remains to be proven. J Clin Oncol 2005; 23: 6450–1
   PubMed Web of Science ®Google Scholar
• Honma I, Masumori N, Sato E, Maeda T, Hirobe M, Kitamura H, Takahashi A, et al. Removal of more lymph nodes may provide better outcome, as well as more accurate pathologic findings, in patients with bladder cancer – analysis of role of pelvic lymph node dissection. Urology 2006; 68: 543–8
   PubMed Web of Science ®Google Scholar
• Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney C, et al. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer 2006; 107: 1491–5
   PubMed Web of Science ®Google Scholar